New combo therapy tested in battle against tough head & neck cancers
Disease control
Completed
This study tested whether adding a new immunotherapy drug (eftilagimod alpha) to a standard treatment (pembrolizumab) works better for people with advanced head and neck cancer that has spread or returned. It involved 171 participants who had not yet received treatment for their …
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC